Literature DB >> 10831344

Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors.

L W Huang1, A P Garrett, D A Bell, W R Welch, R S Berkowitz, S C Mok.   

Abstract

OBJECTIVE: Matrix metalloproteinase-9 (MMP-9) can degrade gelatin and type IV collagen and is known to play an important role in tumor cell invasion across the basement membrane. The tissue inhibitor of metalloproteinase-1 (TIMP-1) is able to prevent activation of pro-MMP-9 and forms a 1:1 complex with the active form of MMP-9. The aim of the present study was to investigate the expression of MMP-9 and TIMP-1 in benign, borderline, and invasive epithelial ovarian tumors.
MATERIALS AND METHODS: A total of 90 patients with epithelial ovarian tumor were treated at the Brigham and Women's Hospital and were used as the study population. Immunohistochemistry and in situ hybridization were performed to detect protein and mRNA expression of MMP-9 and TIMP-1.
RESULTS: In the 90 epithelial ovarian tumors tested, MMP-9 expression in tumor cells was found to be significantly enhanced in serous and mucinous ovarian carcinomas compared with benign and borderline tumors. We also observed the immunostaining of MMP-9 in stromal cells of benign, borderline, and invasive epithelial ovarian tumors. Moreover, the expression levels of TIMP-1 in tumor cells were significantly higher in borderline and invasive ovarian tumors than in benign tumors.
CONCLUSION: Using an in situ hybridization technique, we disclosed a direct correlation between the presence of mRNA and protein expression for both MMP-9 and TIMP-1. The present data suggest that high levels of MMP-9 protein in invasive epithelial ovarian carcinoma are strongly associated with tumor cell invasion. Enhanced expression of TIMP-1 protein in borderline and invasive tumors indicates that endogenous TIMP-1 protein may play a paradoxical role in ovarian tumor progression. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10831344     DOI: 10.1006/gyno.2000.5806

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  13 in total

1.  Integrin regulation of beta-catenin signaling in ovarian carcinoma.

Authors:  Rebecca J Burkhalter; Jaime Symowicz; Laurie G Hudson; Cara J Gottardi; M Sharon Stack
Journal:  J Biol Chem       Date:  2011-04-25       Impact factor: 5.157

2.  Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer.

Authors:  Anika Agarwal; Lidija Covic; Leila M Sevigny; Nicole C Kaneider; Katherine Lazarides; Gissou Azabdaftari; Sheida Sharifi; Athan Kuliopulos
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

3.  Deep depletion of abundant serum proteins reveals low-abundant proteins as potential biomarkers for human ovarian cancer.

Authors:  Biaoyang Lin; James T White; Jian Wu; Shashikant Lele; Lloyd J Old; Leroy Hood; Kunle Odunsi
Journal:  Proteomics Clin Appl       Date:  2009-07-01       Impact factor: 3.494

4.  Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer.

Authors:  Karina Dahl Steffensen; Marianne Waldstrøm; Rikke Kølby Christensen; Annette Bartels; Nils Brünner; Anders Jakobsen
Journal:  BMC Cancer       Date:  2010-05-07       Impact factor: 4.430

5.  TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients.

Authors:  Sven Mahner; Linn Woelber; Christine Eulenburg; Joerg Schwarz; Walter Carney; Fritz Jaenicke; Karin Milde-Langosch; Volkmar Mueller
Journal:  BMC Cancer       Date:  2010-04-13       Impact factor: 4.430

Review 6.  Activated epidermal growth factor receptor in ovarian cancer.

Authors:  Laurie G Hudson; Reema Zeineldin; Melina Silberberg; M Sharon Stack
Journal:  Cancer Treat Res       Date:  2009

7.  The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer.

Authors:  Aparna A Kamat; Mavis Fletcher; Lynn M Gruman; Peter Mueller; Adriana Lopez; Charles N Landen; Liz Han; David M Gershenson; Anil K Sood
Journal:  Clin Cancer Res       Date:  2006-03-15       Impact factor: 12.531

8.  Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent e-cadherin loss in ovarian carcinoma cells.

Authors:  Karen D Cowden Dahl; Jaime Symowicz; Yan Ning; Elisa Gutierrez; David A Fishman; Brian P Adley; M Sharon Stack; Laurie G Hudson
Journal:  Cancer Res       Date:  2008-06-15       Impact factor: 12.701

9.  Expression of MMP-2, -7, -9, MT1-MMP and TIMP-1 and -2 has no prognostic relevance in patients with advanced epithelial ovarian cancer.

Authors:  Jean-Luc Brun; Annie Cortez; Bénédicte Lesieur; Serge Uzan; Roman Rouzier; Emile Daraï
Journal:  Oncol Rep       Date:  2011-12-22       Impact factor: 3.906

10.  The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation.

Authors:  A Paju; T Sorsa; T Tervahartiala; E Koivunen; C Haglund; A Leminen; T Wahlström; T Salo; U H Stenman
Journal:  Br J Cancer       Date:  2001-05-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.